Publication
Efficacy, safety, and mitochondrial mechanisms of myricetin in a preclinical model of trastuzumab-resistant HER2+ breast cancer.
Yaqing Zhu, Wenjuan Yang, Gege Guan, Cuiling Zhou
Toxicology in vitro : an international journal published in association with BIBRADec 1, 2026PMID 42586176doi:10.1016/j.tiv.2026.106294 Journal ArticlepubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260911-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Trastuzumab resistance remains a major clinical barrier in the treatment of HER2-positive breast cancer. To identify therapeutic candidates capable of overcoming resistance, we established trastuzumab-resistant derivatives of SKBR3 and BT474 cells and performed a high-throughput screen of a…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Breast Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.